Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 18, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.m.
View HTML
Toggle Summary ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference
Encouraging preliminary safety and clinical activity data confirm miransertib’s potential for treating PS and PROS patients Registrational study, MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children), expected to begin enrollment in Q3 2019 BURLINGTON, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting
-ARQ 531 demonstrates substantial anti-tumor activity and favorable safety profile -Four of six evaluable CLL patients, all with the BTK-C481S mutation, from cohort 7 (65 mg) experienced a Partial Response -Partial Response also observed in the study’s first Richter’s Transformation patient -Call
View HTML
Toggle Summary ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
Presentation highlights preliminary results from phase 1/2 study of miransertib in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 10, 2019-- ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results
View HTML
Toggle Summary ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)
Presentation highlights phase 1 dose escalation study in patients with relapsed or refractory B-cell lymphoid malignancies Conference call and webcast with ArQule management and Dr. Jennifer Woyach , Principal Investigator, to be held Friday, June 14, 2018 at 8:00 a.m.
View HTML
Toggle Summary ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--May 30, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, Peter Lawrence , President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Jefferies 2019
View HTML
Toggle Summary ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--May 15, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Dr. Marc Schegerin , Chief Financial Officer and Head of Strategy, will present at the 20 th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 at 9:30 a.m.
View HTML
Toggle Summary ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--May 14, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at the 2019 RBC Capital Markets Global Healthcare Conference
View HTML
Toggle Summary ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--May 8, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence , President and Chief Operating Officer, and Dr. Marc Schegerin , Chief Financial Officer and Head of Strategy, will present at the Bank of America Merrill Lynch 2019 Health Care
View HTML
Toggle Summary ArQule Reports First Quarter 2019 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--May 1, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter, 2019. For the quarter ended March 31, 2019 , the Company reported a net loss of $10,267,000 , or $0.09 per
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.